Biogen Inc. (BIIB) Earnings Call Transcript & Summary

August 1, 2024

NASDAQ US Health Care Biotechnology earnings 70 min

Earnings Call Speaker Segments

Chuck Triano

executive
#1

Thanks, and hello everyone, whether it's morning or afternoon, and thanks for joining Biogen's Q2 2024 earnings call. On this call, forward-looking statements will be made, and those carry risks and uncertainties that could lead actual results to differ materially from what those statements say. In our SEC filings, we give a comprehensive list of risk factors, and I'd encourage you to take a look at it. You can find our earnings release and other documents about our results, plus the reconciliation between GAAP and non-GAAP results discussed on the call, in the Investors section at biogen.com; the slides that will be used on this call have also been posted on our website; joining me today are our President and Chief Executive Officer, Chris Viehbacher; our Head and President of North America; Alisha Alaimo; Dr. Priya Singhal, Head of Development; Mike McDonnell, Chief Financial Officer; and from HI-Bio, Dr. Travis Murdoch will be introduced on the call. We'll offer some opening comments, and after that we'll move to the Q&A session. And so we can get through as many questions as possible, we ask that you limit yourself to one question. With that, I'll now turn the call over to Chris.

Chris Raymond

analyst
#2

Thanks, Chuck. There's plenty for us to get through today. First, though, besides our usual group of Priya, Alisha, and Mike, I want to extend a welcome to a fresh face on our team, Dr. Travis Murdoch. Travis is a physician whose training was in gastroenterology, and he later pursued immunology as a Rhodes scholar at Oxford. After spending time at McKinsey, Third Rock, and SoftBank, he took on the roles of Founder and CEO at HI-Bio. It's a pleasure to have Travis and the HI-Bio team joining Biogen. Once again we have a West Coast presence. And the HI-Bio team, collaborating with their Biogen colleagues located on the East Coast, will push ahead with developing felzartamab; so this morning we're reporting really solid quarterly results, though I'd describe this as a quarter that has stretched across 18 months. I believe the — what we're showing today truly mirrors the effort Team Biogen has put in to remake our company. 18 months back, our company had seen 4 years of shrinking revenue and profit. And throughout the past 18 months we've worked quite relentlessly to reverse that and build a fresh future. During the Q4 earnings in February of 2023, we laid out 5 priorities. Priority one was concentrating on new launches. The second involved lowering our cost base and matching resources to growth opportunities. Third came directing our R&D investments toward the most promising assets while enhancing the risk-reward profile. Fourth was optimizing the portfolio we already had, and fifth was growth through external means; we've encountered a few setbacks along the way. Even so, I believe today's results genuinely demonstrate that Biogen has delivered on its promises. And for me, that has always mattered in business. So taking each of them in turn, if we examine our new product launches, every one of the launches is either meeting or exceeding expectations. I'm especially pleased by the very strong results for LEQEMBI, not just in the U.S., but also because there's been a highly successful launch in Japan. And the early data coming from China are also very encouraging, and Alisha will say more on that. A year ago, we set out to lower our cost base, and we are more than on track to deliver those results, and you can see that not only in the OpEx reduction but in the very strong margin improvement, and Mike will discuss that. But something you won't find in the P&L that makes me particularly proud is that even as we've really cut our cost base and boosted our margins, we've invested heavily where it's needed for growth opportunities, both in LEQEMBI and the other launches, but also in genuinely trying to accelerate some of the key R&D assets. Priya's going to get into more detail on this, but BIIB080 stands to gain from it, and litifilimab is another one that benefits. Now, even though our MS portfolio has been shrinking because competition has picked up — especially from biosimilars and generics — we still had several products with lengthy patent protection remaining. SPINRAZA was one of them. And I'd say its performance has been quite good; this space is fiercely competitive. Yet SPINRAZA has managed to hold its ground. Back when I first came to the company, most folks were forecasting that it would fall off. These days, the unevenness tends to show up in certain countries where we ship only occasionally. Take Russia — we do a single shipment there each year. So that business has always been somewhat uneven. Still, if you look at market share, SPINRAZA has performed very well in my view. And it makes me very happy to see VUMERITY back to growing at double digits in the U.S. Within the oral segment of MS, it's the sole product with patent protection. We're seeing a tremendous amount of activity on the injectable side, but the oral segment has remained more or less flat. That's a terrific opportunity, and I'm delighted that Alisha and her team are truly capitalizing on it. Beyond that, we've always stated we'd remain open to growth from external sources. And I'd say the Reata deal from last year is genuinely beginning to bear fruit; the launch is going very strongly not just in the U.S. but by now in Europe as well. As you're aware, our pattern is to get patients onto access programs, with reimbursement coming afterward. But by the close of this year, we anticipate approvals in 20 countries. And we couldn't be happier about that. ZURZUVAE tackles an enormous unmet need, and that launch too is running well ahead of what we expected. So sitting here today, I'd tell you the results you're looking at aren't merely, as I mentioned, the outcome of what happened in the second quarter. Rather, I believe we're now putting points on the board that are finally showcasing all those initiatives we set in motion last year, and we're beginning to make good on them. Of course, we still have work ahead. And I believe there's a genuine chance to keep building a platform for sustainable growth, which we'll pursue in 2 ways. First, now that R&D has been prioritized, I view the Alzheimer's portfolio as a core franchise for us over the years to come. Clearly we'll keep investing heavily in LEQEMBI with the maintenance indication and the subcutaneous version; beyond that, I think the AHEAD study could, if we truly obtain the evidence, demonstrate just how much early treatment matters. Priya's going to cover this, though the 36-month results we presented at AAIC this week matter enormously for LEQEMBI's future growth. That said, we've long understood other modalities would come along too; and tau, I think, is shaping up as a hugely significant modality when it comes to treating Alzheimer's. Biogen, I'd say, is plainly out in front there. Once more, Priya will have more to say on that; we're also witnessing a lupus portfolio starting to take shape; there's a readout coming later this year for dapirolizumab, which we share with UCB. Still, litifilimab has us pretty enthusiastic, for SLE and cutaneous lupus alike; and we're adding one more piece to the lupus portfolio through felza, since that one is actually in Phase I for lupus nephritis. As for me, and Travis will dig into this further, the HI-Bio acquisition carries huge weight for our growth outlook over the longer term. Here's a chance to lay out a group of opportunities whose risk-benefit profile differs from the rest. Our Phase II results are very strong, and that hands us far more confidence going into Phase III than we get from certain other assets sitting in our portfolio. Neuroscience addresses a tremendously important unmet need, yet it also ranks among the riskiest and most difficult spaces.

Alisha Alaimo

executive
#3

So I believe pursuing immunology programs gives our portfolio a bit more balance, and on a personal level I'm very enthusiastic about felza and about what Travis and the team there are capable of achieving. Another avenue here is that we will keep exploring business development. You've probably noticed how disciplined we tend to be. The two acquisitions completed to date, Reata and HI-Bio, should generate a great deal of shareholder value, and that consideration stays front and center whenever we evaluate business development. So Biogen today looks quite different from where it stood 18 months ago. Like any company, we still face a number of challenges, but I believe the company is now genuinely set up for longer-term growth. With that, I'll hand things over to Alisha for additional detail on how the launches are going.

Alisha Alaimo

executive
#4

Thanks, Chris, and good morning, everyone. I appreciate you being on the call today. I'll share our view of how LEQEMBI, SKYCLARYS and ZURZUVAE are progressing. Starting with the Alzheimer's market: we feel we're building momentum, with more health systems nationwide now able to handle a greater volume of Alzheimer's patients. Those encouraging trends carried on through Q2. In particular, we kept up new patient growth. Almost 40% of all commercial patients on therapy since launch began treatment in Q2. The count of physicians who prescribe LEQEMBI rose 50% as well. Ordering depth at our Priority 100 IDNs kept accelerating, and overall order volume again more than doubled in Q2 versus Q1. It's worth noting that according to the data available so far, these patterns persisted through the first weeks of July, which shows we're maintaining launch momentum. We also think we're seeing encouraging signs that health system capacity could be expanding. For instance, in the prior quarter I talked about how certain IDNs are growing and extending their care sites. During Q2, almost 70% of activated Priority 100 IDNs went beyond their flagship locations to treat patients at their trial sites, and we've observed this same dynamic occurring outside the priority IDNs too. We think expanding real-world experience with LEQEMBI's efficacy and safety makes its distinctive profile even stronger in a market that has newly become competitive. In particular, some HCPs say that since LEQEMBI was studied in the broadest and most diverse population of any anti-amyloid drug so far, it eliminates some of the complicated deliberation over which potential patients are suitable for Alzheimer's treatments. Alzheimer's is a chronic, degenerative and fatal disease that doesn't halt even once plaque has been removed. Indeed, our long-term data indicate that patients who ceased LEQEMBI treatment saw key plasma biomarkers re-accumulate rapidly, signaling that Alzheimer's disease biology was coming back. What's key here is that for most patients who halted their medication, the speed at which they declined went back to what was seen among those on placebo. That's the reason we feel patients are deserving of a treatment whose benefit-risk balance allows them to keep taking it, so they can stay in front of disease progression — even once plaques have been cleared — by stopping further damage and plaque accumulation. Fresh data that Priya is going to walk through supports the idea that for patients on therapy continuously for 3 years, LEQEMBI delivered sustained advantages. And last, while head-to-head trials pitting the existing therapies against one another don't exist, the FDA has stated plainly that how often ARIA occurs and when it strikes differs across drugs in this class. The ARIA rates seen among patients given LEQEMBI came in as the lowest ever reported in any Phase III study for a drug holding traditional FDA approval within the class, with LEQEMBI's rates almost 50% lower. To drive home LEQEMBI's distinct profile with our customers, Biogen rolled out our bigger field force only last month. This group sharpens our focus and boosts our frequency with high-value sites, while widening our reach to 30% more HCPs. Feedback since this team launched has been positive. Biogen's field force is collaborating with our partner, Eisai, even more tightly, and we think that's sharpening our customer insights and will pave the way for faster growth. Two solid quarters of growth plus continued momentum in July have us feeling good, and we're eager to give still more backing to the healthcare community and to people living with Alzheimer's disease; shifting now to the SKYCLARYS update, where our launch momentum remains strong as we reach more Friedreich's ataxia patients around the world. During the second quarter, we brought in $100 million in global revenue and are still running above our own internal targets. The Europe launch is exceeding internal projections and, together with rest of world, extends the success achieved in the U.S. SKYCLARYS can now be found in 12 markets outside the U.S., the EU among them, where we're starting new patients within the catch-up population. These individuals and their HCPs are deeply involved in their care and frequently were waiting on SKYCLARYS approval, which is standard for rare disease launches. Stateside, we've gone past the catch-up population, since SKYCLARYS has now been on the market for over a year. The team keeps drawing on our robust rare disease capabilities, and the early results from engaging patients and physicians in this next phase have us feeling good. During Q2, about 1/3 of new patient start forms originated from new riders linked to our AI program, which sorts through hundreds of thousands of de-identified patient journeys; a meaningful share of that comes from community neurologists and PCPs. Around the world, our FA outlook looks promising both near term and long term. We expect to generate strong growth by bringing SKYCLARYS to additional geographies and potentially expanding into pediatric populations. And given our years of experience finding patients, we think we can make a difference. Moving to ZURZUVAE; we keep beating our expectations across the first 6 months of launch. During Q2, we experienced impressive expansion, as U.S. revenue climbed 19% while patient demand almost doubled compared with Q1. Prescribing continues to be led by OB-GYNs, and those patients are telling their doctors and posting about their encouraging initial results on social platforms. According to market research we conducted recently, we think aided awareness of ZURZUVAE among providers has reached above-average levels, beating messaging recall benchmarks in women's health and psychiatry. To reach the next stage of expansion and further our goal of changing postpartum depression care, we're focused on gaining a deeper grasp of how to unlock the patient opportunity within this market and generate genuine behavioral shifts; so in closing, though no two launches are alike, we're happy to report that across all 3 therapies we continue to meet or exceed what we anticipated; we recognize there's still much to accomplish for those dealing with Alzheimer's, Friedreich's ataxia and postpartum depression, and we're moving swiftly to support these patient communities. Now I'll hand things over to Priya.

Priya Singhal

executive
#5

Alisha, thanks. Throughout this past year, a major priority has been taking a hard look at the pipeline we already have, aiming to make its risk profile better. What we're concentrating on now is expanding that pipeline by drawing on opportunities from inside as well as outside, with the goals of spreading risk and generating value. We're equally committed to putting money behind efforts to succeed in Alzheimer's disease, a space where LEQEMBI, in our view, stands out as a differentiated product, and where we have a research and development pipeline of possible next-generation therapies that leads the industry. Starting off with LEQEMBI. Among approved anti-amyloid antibodies, LEQEMBI is the sole one possessing, number one, a dual mechanism of action that goes after amyloid plaques as well as highly toxic protofibrils; number two, clinical data spanning the entire early Alzheimer's disease population, covering people with no tau and low tau alike; and number three, broad real-world evidence. As Alisha pointed out — and this matters — Alzheimer's disease is a chronic, progressive condition, so in our view the dual action that LEQEMBI provides, plus the choice of ongoing treatment, gives patients seeking to keep or build on clinical benefit an advantage that nothing else offers. Along those lines, at AAIC earlier this week, Eisai shared 3-year data coming out of the Phase III Clarity study along with its open-label extension, and that data demonstrates sustained clinical benefit when LEQEMBI treatment lasts longer. On the left, you can see this covers data from the early start group, meaning those who began LEQEMBI while the 18-month placebo-controlled phase of the study was underway; the delayed start group, meaning patients in the placebo arm who moved to LEQEMBI once the open-label extension began; and a baseline-matched natural history cohort drawn from ADNI. What the early start group demonstrates is that 3 years of uninterrupted LEQEMBI treatment lowered clinical decline by negative 0.95 on CDR-Sum of Boxes relative to the natural history cohort, which translates into a clinically meaningful benefit for early AD patients. That amounts to an extension of the benefit seen at 18 months; something very important to remember is that going from 0.5 to 1 on the CDR score domains covering memory, community affairs, home and hobbies marks the difference between slight impairment and loss of independence. In our view these results matter greatly, since approximately 70% of individuals — the majority — had already successfully cleared plaque by the 18-month mark. On top of that, data from the lecanemab Phase II study, visible on the right, which had a treatment gap averaging roughly 2 years, demonstrates that even after plaques are gone, Alzheimer's disease keeps progressing if treatment gets stopped or interrupted. Eisai also presented data at AAIC showing that among patients in the Clarity AD study with no tau or low tau — an early stage of Alzheimer's — 51% demonstrated improvement from baseline in cognition and function across a 3-year period, as measured by CDR-Sum of Boxes. All these findings point to the possibility that starting lecanemab sooner could substantially slow the course of the illness and might keep delivering advantages to early Alzheimer's patients over an extended period. Our attention remains fixed on LEQEMBI, with the objective of pinning down the right dosing to secure long-term gains, offering flexibility through a subcutaneous version, and assessing what role it might play in the preclinical AD group, as Chris noted. Turning to the CHMP's negative opinion on lecanemab, that news let us down; even so, we hold the view that the clinical evidence reveals an unmistakably favorable benefit-risk balance delivering meaningful clinical value to those affected. On top of that, lecanemab has now been given to thousands of patients around the world, which supplies additional real-world proof regarding both its effectiveness and its manageable safety profile. We keep collaborating with Eisai as they intend to seek a reexamination of the EU filing, all while striving to open up access for Alzheimer's sufferers everywhere. In addition, we remain committed to funding our wider Alzheimer's pipeline, which includes BIIB080, our investigational anti-tau ASO. Given the encouraging results from the Phase Ib trial, we have implemented a protocol amendment for the Phase II CELIA study that is currently running, intending to speed up a possible proof-of-concept result. It excites us that this amendment, together with the strong enrollment patterns seen so far, might make a readout possible in 2026. Past amyloid and tau, and with Jane leading our research, we are pushing forward a preclinical AD pipeline spanning varied targets and modalities, among them active transport strategies. As we announced today in our earnings release, we chose to end the ATV:A beta collaboration with Denali. We still recognize value in modalities capable of actively transporting therapeutic agents into the brain, and we keep giving priority to such work as we aim to extend the leadership position we already hold in AD. Reflecting on recent months, although we halted 3 mid-stage programs because of their readouts, we are still achieving progress in numerous other pipeline areas. A first patient has been dosed with SKYCLARYS in Biogen's Phase I dose-finding trial for pediatric Friedreich's ataxia. That marks the initial move toward possibly broadening SKYCLARYS access into the pediatric population. Once we settle on a dose, our plan is to run a Phase III study evaluating benefit risk among pediatric patients. We also anticipate that the DEVOTE study, which is testing high-dose SPINRAZA, will report results during this second half of the year. Meaningful strides have also been made in immunology, where the first patient was dosed in the litifilimab Phase III portion of the operationally seamless Phase II/III AMETHYST study in CLE, following completion of Phase II enrollment. As Chris noted, immunology remains, in our view, a major potential engine of Biogen's future growth, and the recent HI-Bio acquisition illustrates how important this is. With that, I'd like to pass the call to Travis, who will explore felzartamab in a bit more depth.

Travis Murdoch

executive
#6

Thank you, Priya. It's a real pleasure to be speaking with all of you today as a member of the Biogen team. In my view, we have a rare chance to bring together HI-Bio's know-how in immune-mediated indications and Biogen's worldwide development and commercialization capabilities in specialized immunology and rare diseases. This combination, I believe, will deliver substantial upside as we push to move our lead asset, felzartamab, or felza, quickly into late-stage development. Felzartamab is an anti-CD38 antibody, and we think it possesses a differentiated molecular design that selectively targets and depletes the plasma cells that produce pathogenic antibodies, without harming the wider B cell lineage; that sets it apart from other programs now in development for antibody-mediated diseases, which affect B cells more broadly. Relative to other mechanisms, we expect the specificity of felza's MOA to yield a differentiated and more desirable clinical profile, one marked by efficacy that lasts longer and an improved safety profile. As Chris noted, optimizing the risk reward of the pipeline is one of Biogen's objectives, and I think acquiring felza moves that effort forward considerably. Felza has already demonstrated clinical proof-of-concept across several rare immunology indications by depleting cells. Antibody-mediated rejection, or AMR, IgA nephropathy, or IgAN, and primary membranous nephropathy, or PMN, are severe conditions that cause serious outcomes for patients, such as transplant failure or end-stage kidney disease. Available therapeutic options leave a significant unmet need, so we believe there's a sizable commercial opportunity here. Let me now quickly review the felza data we've generated to date in these indications, to underscore the potential value we see for patients. In the U.S., AMR is the top reason kidney transplants are lost, and there are no approved treatments. Also, earlier investigational agents haven't shown meaningful resolution of AMR biopsy. If this isn't addressed, the outcome can be severe — patients may lose the graft, require dialysis, and in many instances need another transplant. In our Phase II trial, the findings of which appeared in the New England Journal of Medicine, giving 9 doses of felza IV across a 5-month span led to AMR resolution in over 80% of cases by week 24, compared with 20% among those on placebo. On top of that, among responders, 2/3 kept their AMR resolution through 52 weeks. Given that, our view is that should a registrational study reproduce these findings, they could be potentially transformative for this disease. Moving on, let’s talk about IgA nephropathy, or IgAN. It’s the most common chronic glomerular disease globally, and it’s another condition where we think felza could offer patients a treatment choice with meaningful differentiation. Felza works by directly depleting CD38-positive plasma cells — the cells responsible for producing both galactose-deficient IgA1 and its autoantibody, which are thought to be the most upstream drivers of IgAN. On this slide, you can see that felza led to sustained IgA reductions lasting as long as 24 months, which is over 18 months past the final dose. Notably, that pharmacodynamic effect targeted IgA specifically, while IgG and IgM came back to baseline once the 5-month course of felza was finished. When you put these findings together with the clinical efficacy data that's starting to come out, it points toward felza having a selective impact on IgA that lasts, which would mean it can affect how IgAN disease biology works, and at the same time it may let patients keep the general protective immunity that comes from IgG and IgM antibodies across an extended stretch with no therapy. Much like what we observed with IgA, the interim data from the Phase II IGNAZ study demonstrated a lasting drop in proteinuria measured through UPCR. To be specific, the reduction in UPCR depended on dose, and it held up through the 24-month time point. When it comes to how this might stand apart, one thing worth flagging is that this improvement appears after patients have been off therapy for more than 18 months, which backs the possibility that felza could become the first non-chronic treatment option in IgAN. On top of that, consistent with how it selectively targets plasma cells, felza was generally well tolerated when given, and its safety profile matched what earlier studies showed. Our view is that these interim results may open up a broad therapeutic window and could eventually bring down the risk tied to chronic immunosuppression, a benefit that might matter a great deal for IgAN patients. Turning to PMN. This is a serious antibody-mediated kidney disease and a top cause of nephrotic syndrome, a severe condition that arises when too much protein is excreted in urine and that produces symptoms like swelling, fatigue and a higher chance of infection. The current standard of care, which takes in immunosuppressive and chemotherapeutic agents, has shown itself to be inadequate, since as many as 40% of patients never reach remission. And a large number go on to end-stage kidney disease. Estimates suggest that as many as 80% of PMN patients carry autoantibodies against PLA2R, a kidney antigen, and that gives us a crucial biomarker for stratifying patients and for tracking treatment response. In the Phase II M-PLACE trial, we evaluated felza among patients who were newly diagnosed or had relapsed, as well as individuals refractory to immunosuppressive therapies. Over a 24-week course of felza, we observed a rapid, pronounced, and sustained drop in anti-PLA2R antibodies across both cohorts at the one-year mark. Many patients maintained an immunologic complete response past six months after receiving their final dose of felza, which highlights just how long-lasting the treatment's effect proves to be. Of note, the changes in anti-PLA2R corresponded to the declines observed in proteinuria. And as has been the case in prior felza trials, TEAEs were predominantly mild or moderate in severity. Given these findings, our belief is that felza may deliver a meaningful new treatment for people living with PMN; all told, we think the data gathered so far underscores felza's potential to be a best-in-class option for several serious immunologic diseases where unmet need remains significant. Phase II data spanning AMR, IgAN and PMN have delivered proof-of-concept and pointed to a clinical profile that may be differentiated when it comes to efficacy, how long treatment effects last, and safety. Looking ahead, I'm eager to bring together what the HI-Bio and Biogen teams can do jointly, applying what we've learned as we keep sharpening the design for our Phase III effort. At this point, our expectation is to launch Phase III trials in AMR, IgAN and PMN during the coming year, with AMR coming first in the initial six months. At this stage, I'll hand things over to Mike so he can walk through the financials.

Mike McDonnell

executive
#7

Thanks, Travis, and good morning, good afternoon, everyone. First off, I'd like to give credit to the entire Biogen team for a strong second quarter. I'm glad to walk you through some thoughts on how things went, and I'd ask you to remember that all of my comparisons are being made versus the second quarter of 2023. We brought in total revenue of $2.5 billion, a modest increase over the same period last year in actual currency, and a 1% gain in constant currency; even more significant, though, is that revenue from our core pharmaceutical business grew 5% in actual currency and 6% in constant currency. The driving force behind that increase was how our 4 recent launches performed, and those results were enough to more than cancel out the softness in our MS business. On a non-GAAP basis, diluted earnings per share climbed 31%, reaching $5.28, and that figure contained a $0.52 one-time gain tied to selling one of our two priority review vouchers. Excluding that PRV transaction, non-GAAP EPS would have come in at $4.76, an 18% increase. Non-GAAP operating income improved 43%, or 30% once you set aside the PRV sale. Our R&D prioritization work and Fit for Growth efforts continue to pay off, and I'll cover those in greater depth shortly. We're pleased to be lifting our guidance range for the full year 2024. I'll pass along a few more specifics about that guidance in just a moment; first, let me add some further context regarding second quarter revenue. In the quarter, revenue for our MS franchise was down roughly 5%, and there are a few dynamics in this business worth calling out. To start, our interferon business continues to erode as the whole class shifts toward oral or higher-efficacy therapies. On the TECFIDERA front in the EU, most generics have now left the market, and that contributed to ex U.S. growth of 11% at actual currency and 12% at constant currency, reaching $208 million this quarter. Our position remains that we are entitled to market protection in the EU through February of 2025. For VUMERITY, this was its strongest quarter since launch, with global revenue up 13% at actual and constant currency to $166 million. In the U.S., VUMERITY continues to hold the top spot among branded orals when it comes to share. TYSABRI's U.S. sales came in at $249 million, a 4% drop, which got a boost from shipment timing during the quarter but was held back by competitive pressures in the high-efficacy category. Turning to rare disease, that franchise brought in $534 million, up 22% at actual currency and 25% at constant currency. SKYCLARYS generated $100 million worldwide. SPINRAZA's global revenue reached $429 million, down 2% at actual currency and unchanged at constant currency. In the U.S., revenue rose 1% to $157 million, and we continue to feel good about the resilience there. Turning to LEQEMBI, we experienced substantial growth from one quarter to the next, with global in-market sales recorded by Eisai hitting roughly $40 million in Q2, and that figure encompassed $30 million coming from U.S. in-market sales. Now I want to offer a few comments about our expenses. Non-GAAP cost of sales as a share of revenue continues to arrive at a lower level, which came about because of a more advantageous product mix. Specifically, this shows the ongoing expansion of SKYCLARYS, which is taking the place of revenue from contract manufacturing that brings in thinner margins. Beyond that, we had no idle capacity charges during this quarter, whereas in the second quarter of 2023 those charges totaled $34 million. As I noted earlier, our R&D prioritization along with our Fit for Growth initiatives have started to deliver meaningful gains in profitability. Non-GAAP R&D expense for the second quarter fell by $120 million, or 21%, relative to the second quarter of 2023, as our spending remains concentrated on programs most likely to succeed. Non-GAAP SG&A expense rose 1% during the second quarter; we've cut selling costs for legacy products considerably and also brought down our general and administrative cost base substantially, which let us absorb the bulk of roughly $100 million in incremental launch costs during Q2 2024 for LEQEMBI and SKYCLARYS; now a quick update regarding our balance sheet. We closed the second quarter holding $1.9 billion in cash and marketable securities. Keep in mind that we drew down $1.15 billion from that balance in July upon completing the HI-Bio acquisition; net debt stood at approximately $4.4 billion at quarter's end. During the quarter, we paid off in full what remained of the $1 billion term loan arranged when we acquired Reata; and we kept generating robust cash flow in the second quarter, with free cash flow of roughly $592 million, taking us to about $1.1 billion in free cash flow for the first half of 2024; we still believe our balance sheet gives us the room to invest in growth opportunities both internal and external. Now for our outlook. We're pleased that how the business has performed operationally through this point in the year allows us to raise our 2024 full-year non-GAAP diluted EPS forecast. Previously we had pegged it at $15 to $16; the new target sits between $15.75 and $16.25. Taking the middle of that span, it works out to roughly 9% growth compared with what we delivered across all of 2023. As you refresh your models, I'd like to point out a few key items for the back portion of 2024. Turning to revenue: because demand for our main offerings is tracking either around or a bit ahead of what we projected, we're nudging the outlook for the year slightly upward. The current expectation is that total revenue for the full year will fall by a low single-digit percentage compared with 2023. In addition, we expect core pharmaceutical revenue to be approximately level versus last year, since newer launches ought to gain ground and counterbalance certain dynamics that could weigh on the latter half of the year. Among those is the continued pressure we foresee on our MS franchise, which accounts for the chance that a biosimilar competitor could enter the U.S. market for TYSABRI. And we keep watching shipment timing for SPINRAZA in certain ex U.S. markets. Moving on, the divestiture of one of the 2 priority review vouchers we hold represents a one-time event. Because we intend to put the money from that sale back into growth efforts later in the year, we don't anticipate that gain will affect our EPS for the entire year. There are also several important things to keep in mind about our operating costs. During the back half of the year, we anticipate continuing to increase launch-related spending for our new product introductions. That covers the 30% expansion of the LEQEMBI field force, which is in the process of coming online, plus further investment in certain targeted direct-to-consumer campaigns. Beyond that, we anticipate added OpEx, mainly on the R&D line, of roughly $50 million across the latter half of the year tied to HI-Bio as we carry out plans for 3 possible Phase III starts. Our expectation for full year 2024 combined non-GAAP R&D and SG&A expense remains at approximately $4.3 billion. We recorded roughly $2 billion in spending during the first half of the year, which suggests greater spending in the second half for the reasons I just outlined, together with some normal phasing of expenses across the year. I'd also point out that we now anticipate 2024 operating income growth in the mid-to-high teen percentage range, compared with our earlier guidance of low double-digit percent growth. This upgrade accounts for elevated second-half expenses relative to the first half, partly offset by greater revenue from our new product launches. Let me remind you that we anticipate a decrease in interest income of about $20 million for the rest of 2024, driven by reduced cash balances and the corresponding lower interest income stemming from the HI-Bio acquisition. As is our practice, our guidance excludes any impact from possible acquisitions or major business development deals, or from pending and future litigations, since those are frequently hard to forecast. For additional key guidance assumptions, please see our press release; and right before we begin the Q&A, I'd like to give a quick update on the strategic review of our biosimilars business. Having thoroughly assessed potential externalization options against keeping the business, we conclude that the greatest value for shareholders moving forward lies in retaining the business inside our portfolio and optimizing it with the goal of maximizing profitability. With that said, we'll now open the call for questions.

Chuck Triano

executive
#8

Thanks, Mike. Operator, can we please poll for questions?

Salveen Richter

analyst
#9

Congrats on the quarter. On a broad level, everyone's been watching 2024 closely as the moment things shift for this business, whether that's on the product side with new launches or on operations with the savings initiatives and pipeline reprioritization. With the guidance you just raised—9% EPS growth year over year for this year—could you talk about how confident you feel that 2023 marks the low point for earnings? And what has to happen from here to get clean growth all the way through the end of the decade?

Mike McDonnell

executive
#10

Yes. Thanks for asking, Salveen; our mission here at Biogen is still to deliver sustainable growth on the top line as well as the bottom line. Clearly, the guidance we first put out, which pointed to 5% bottom-line growth at the midpoint and is now 9% at the midpoint, demonstrates that we have now turned the corner on the bottom line. We're heavily focused on our cost savings program, which crucially doesn't just boost our operating performance but also unlocks capital for growth initiatives; that matters a great deal. Clearly, we don't provide guidance past 2024. That said, I'd note that with this year's guidance, we're happy that we've managed to get the top line considerably more stabilized, and we have the bottom line expanding once more as we head into next year. We're happy with how the launches are going. Whether we can restore the top line will depend somewhat on how those launches keep performing, as well as on how the MS franchise keeps sustaining itself and holding up; what I can tell you is that we're intensely focused on returning this company to growth, and we're definitely hopeful that 2023 was the trough year. And clearly, we're doing a solid job expanding the bottom line in 2024. We'll share more about the out years as we get to the back half of this year and into early next.

Mohit Bansal

analyst
#11

Satya here, filling in for Mohit. My question concerns the EMA's decision on LEQEMBI. Are you intending to file further evidence regarding efficacy or safety, whether from trials or real-world data, in order to get that decision overturned? Also, how confident are you that it can be reversed? And what timeline should we have in mind for the EMA to take another look? Would it be necessary to convene a SAG-N for that process?

Priya Singhal

executive
#12

Priya Singhal speaking; alongside Eisai, we're deeply disappointed by the negative opinion issued for LEQEMBI. Our belief remains that the benefit-risk profile is positive and favorable. As you're aware, approval has been granted in major regions globally, including the United States, China, and Japan. And just recently, we communicated approvals in Hong Kong, Israel, and South Korea as well; so yes, this has been communicated publicly, and I can reaffirm that we intend to apply for a reexamination process. Under how reexamination works, you're able to keep working through the process with a newly appointed rapporteur and co-rapporteur. So at this point, we'd await the assessment report from the CHMP. Once the new rapporteur and co-rapporteur are appointed, we would collaborate with them to grasp which issues are behind the decision; and as things stand, given the opinion that was rendered, our view is that these can be addressed using the data we've generated. In particular, long-term data has been generated, as we presented at AAIC. And we would aim to engage with the EMA and CHMP regarding how additional data can be submitted, along with the extensive real-world data in our possession, since thousands of patients have now received treatment. So we have long-term continued benefit, as demonstrated in the 3-month — 3-year data at AAIC, plus long-term safety. So we're continuing to work very closely with Eisai on the reexamination process and strategy. A new SAG-N could potentially be appointed, and generally this process would move faster than the original application.

Evan Seigerman

analyst
#13

Evan Seigerman here. I've got something for Priya. Could you take us through the reasoning behind deciding not to move forward with the Angelman syndrome program alongside Ionis? In what ways has the way you assess partnerships shifted lately? And when you're weighing what to do with a partner, which elements of a program are you now examining more carefully?

Priya Singhal

executive
#14

If I zoom out for a moment, I'd like to direct everyone to things we've said publicly in the past too — we genuinely treat our readouts as key inflection points. When the data come back objectively clear and compelling, that lets us double down and speed those programs up; alternatively, we have the ability to pivot toward other programs we might be looking at. Broadly speaking, our approach involves setting up go/no-go criteria ahead of time. From there, we determine the likelihood of technical and regulatory success for a given program. That's precisely the method we used with the Angelman syndrome, the BIIB121 data. This will remain how we evaluate every one of our readouts, and we aim to stay highly disciplined. Among the things we consider especially compelling are biomarkers, established regulatory pathways, clinical tractability, plus how confident we are in regulatory endpoints or based on our interactions with regulators. So we take all of that into account, and that's the lens through which we think about Phase III investment.

Chris Viehbacher

executive
#15

Let me jump in here as well — beyond what Priya mentioned, something else we're evaluating is whether we can bring products to market worldwide. That means we're also focused on how much evidence is needed and what regulatory endpoints would satisfy payers and regulators across the globe, rather than only those here in the U.S.

Mike DiFiore

analyst
#16

Nice work on the quarter. I wanted to ask whether there's anything new regarding the dose optimization effort for subcutaneous induction that you've been conducting, and whether that might produce a better risk-benefit profile — the kind the EMA is seeking?

Priya Singhal

executive
#17

Sure. Broadly speaking, as Eisai and Biogen have said publicly, we're still moving forward — the IV maintenance filing has already gone in, plus we hold a fast track designation and a rolling submission for the subcutaneous maintenance dose. Once subcutaneous administration begins, our focus is on finding the optimal dose. That work with FDA is ongoing. And right now, as we've shared, we remain on schedule to receive an outcome from the FDA here in the U.S. during Q1 — calendar year Q1 2026. As for your particular question about what this means for the European application, let me be very clear: the European filing we intend to pursue at present, the reexamination, rests on the original submission, which is for intravenous LEQEMBI. Our hope is that we can secure a favorable result when the reexamination concludes; should that happen, we'd keep going along the same path of offering options to patients, including in Europe, with the subcutaneous version.

Nicole Gabreski

analyst
#18

Nicole Gabreski, filling in for Chris, here. I want to touch on LEQEMBI. Our recent survey work with neurologists and Alzheimer's specialists seems to point toward a somewhat less positive take on the risk-benefit and cost-benefit profiles for LEQEMBI over the last few quarters. And I believe we're beginning to pick up feedback from doctors who are also casting doubt on the amyloid hypothesis in general. With that in mind, could you address what reps are encountering in terms of interactions or feedback out in the field? Are you beginning to see any resistance as you shift away from HCPs who were essentially ready and waiting to prescribe LEQEMBI shortly after approval toward those in the following wave of uptake?

Alisha Alaimo

executive
#19

Alisha Alaimo speaking. Any time we review market research, I believe it matters to grasp whom you are actually surveying. So when we examine what's going on in the field, at least at the ground level, when physicians are being asked, if you were to break down market research and ask doctors who clearly are prescribing right now versus those who aren't, the prescribers are the group we've worked extremely hard on throughout this past year. They grasp the data; MSLs have called on them; representatives have called on them; and then it takes time for them, clearly, to get their facility up and running. You also observe broadly that other physicians notice this occurring, and some located closer by will clearly begin taking up the product too; so at ground level, with our representatives, they move from one office to the next. We're clearly growing now too, thanks to the added field force. What we've observed is that whoever you call on is who actually begins writing; and many dynamics are in play here. I believe grasping this data matters. I believe grasping every mechanic needed to get a patient diagnosed matters, and getting their capacity established matters. So we truly don't hear any resistance regarding cost benefit. That I can tell you. And I think even more significantly, what we're now hearing, since we're a year out, is that we're starting to genuinely receive real-world experience feedback from physicians regarding the effect this is having on patients, caregivers, and families; and I believe that by itself has also sped up some of these physicians' efforts to try treating patients even faster. So at this point, we aren't truly hearing that resistance.

Chris Viehbacher

executive
#20

If I may piggyback on that point, having observed this field for many decades, my inclination is to weight physicians' actions more heavily than their words. Introducing this therapy into clinics and hospital systems represents an enormous undertaking for doctors. When you consider the 50% rise in the count of prescribers and how deeply the IDNs are ordering, it's evident that many doctors are pouring tremendous time and effort into navigating every step — lining up PET scans, lumbar punctures, MRIs. To my mind, nobody would bother doing all of that absent a firm belief in how much this treatment matters for patients. So from my own vantage point, I find our current position tremendously heartening. For the first time since launch, I believe we can anticipate this market expanding — and not merely owing to prescription volumes. Consider the body of evidence we're assembling alongside our Eisai colleagues on LEQEMBI; the 3-year data make it quite apparent that clearing plaque alone will likely prove insufficient. Patients will need ongoing treatment. And as I mentioned before, through the AHEAD study, we're hoping to demonstrate that earlier intervention delivers a benefit. So this market will expand, the evidence will expand; what we're engaged in is market building, and that undeniably demands time along with patience. Yet, as I've noted previously, forecasting our trajectory is hard; with this quarter, I believe we're witnessing — we're on quite a firm path. And in my view, Lilly's arrival will merely speed up this marketplace's evolution.

Nevin Varghese

analyst
#21

Hi, this is Nevin, filling in for Brian. Nice work on the quarter, and thanks ahead of time for fielding our questions. I'd like to dig a bit deeper into the SKYCLARYS trends we're observing, particularly regarding patient persistence or possible discontinuation rates. Could you also touch on the educational initiatives you're running to help persuade patients to stay on treatment, even when they aren't experiencing results from the therapy immediately; and perhaps elaborate on any perceptions that patients and physicians might hold concerning cardiac safety and the benefits involved there too.

Alisha Alaimo

executive
#22

Sure. Thanks for asking. This is Alisha. To start, what we're seeing at present makes us quite happy, particularly on a global basis and within the U.S. with SKYCLARYS. As I've said previously, the catch-up population is behind us. At this point we've truly moved into the patient identification stage. We examine each metric — discon, compliance, adherence, start times. Regarding discons, nothing we observe falls outside what shows up in the clinical trials. Therefore the discontinuation rate is nothing beyond, clearly, what we likewise observed in trials. On the subject of efficacy for patients, physicians have done a really strong job setting expectations with patients regarding what to expect from SKYCLARYS. Our field reps also perform really well when it comes to teaching doctors and giving patients educational resources about what to anticipate once they start this product; as a result, you notice that people generally stay on it. Doctors also do a great job of advising patients to remain on the therapy for at least twelve months, then having a conversation about how they feel and what comes next. What we're observing is that adherence has in fact been quite strong. Another factor I believe you may be hinting at is that because we've reached the patient identification phase, there will be some fluctuation from one week or month to the next. Every week brings new patients into our system. The same happens on a monthly basis, and fresh data comes in consistently. Lately — I mentioned this to Chris recently — we've been rolling out a new AI engine, and through it we've pinpointed a substantial group of additional coded FA patients who weren't on our radar when we first launched. The reason is that we're beginning to observe patients interacting with their doctors to a greater degree. As a result, we can now connect with those patients more efficiently and with greater certainty on all fronts. I'd say the early signs are quite encouraging, since we're bringing on new parents—new patients, I mean.

Paul Matteis

analyst
#23

My sense is that during the last 12 months, the way Biogen has talked about its capacity for business development has shifted a couple of times. More lately, I believe you mentioned roughly $10 billion, perhaps not counting the HI-Bio deal. So, as we move ahead into 2024 or the nearer to medium term, how hungry is Biogen for larger deals or something along the lines of a Reata transaction? And what is the latest view regarding particular therapeutic areas or kinds of assets you find interesting?

Chris Viehbacher

executive
#24

Yes, that one's mine. First, regarding where we are searching, we are already heavily weighted toward neuroscience. That means we are likely to look beyond that area, at immunology and rare diseases. When I consider Biogen, I would describe us as having a very strong scientific and medical capability internally. Historically, we have been a company operating in the low-volume, high-value segment. We genuinely grasp the need to help patients and physicians with certain costly products to secure reimbursement, and to provide and sponsor genetic testing, as one example. Considering studies and real-world evidence turns out to be very significant here. So Biogen does have a capability in rare diseases. Immunology is truly a field we have occupied ever since our beginnings with multiple sclerosis. Thus, I believe we possess the capabilities to move into those fields. What I see now is that we are following a growth trajectory. If another acquisition of the Reata type could be found, I believe we would pursue it. Yet those appear quite infrequently. It is uncommon to locate a company so near to the market; in fact, it had already launched when we actually bought it, but we bought it at a price that still generates shareholder value. And we will keep searching, but they do not appear daily; and we are not in a situation where I believe we are desperate to complete a deal; so we — I think if you consider what we did with HI-Bio, as one example, as a substitute for that, being able to bring more products to market in roughly the 2027 to 2030 window is a priority for us; and that is why we are also strongly concentrated on the mid- to late-stage development process. But we have the luxury of being picky. Additionally, I think the places we look are not always the places everyone else looks. You truly do not generate value by participating in these auction processes. And so I think by managing to remain in those areas where we believe this is a really — this is a space where Biogen can truly be a strong player, we will steer clear of overpaying. Another point I would make is that Biogen is a good size. $1 billion makes a huge difference in our company. There are many larger companies where $1 billion fails to make a difference. So I'd say there are assets out there for us to consider — ones that require more money than some of the larger companies would want to commit, yet cost more than some of the smaller ones could afford. In a sense, then, our situation lets us pursue those assets without landing in the fiercely contested spaces where, once again, you run the danger of paying too much. Still, we are searching. Our approach is methodical. We won't make any abrupt strategic pivots, simply because I doubt that such moves represent the true sweet spot for Biogen; even so, I believe plenty of possibilities exist. Beyond that, we're expanding our efforts considerably in research and through collaborations; and one thing I'd genuinely like to see from us is pulling far more assets in at an early stage, since the sooner you can bring such assets aboard, the greater the shareholder value you're able to build.

Michael Yee

analyst
#25

During the earlier portion of this call, you brought up a lupus portfolio that's emerging, and I'm aware there's some lupus data coming soon; we've reviewed what was reported previously. There are grounds to think that a longer duration of treatment along with a larger trial might be beneficial in this case. Could you share what you're anticipating? What exactly are you hoping to see? What would have to occur for things to progress, and so on and so forth?

Priya Singhal

executive
#26

Yes. Thanks. Priya Singhal here. Broadly speaking, we're enthusiastic about the dapi readout. It's coming in the next several weeks. This program is partnered, and the collaboration is going very well; we anticipate a headline on top line results from the first global Phase III trial. To be specific, I'd like to make it clear that this trial is examining, in this area of very high unmet disease need, how safe and effective dapi is when added on to standard SLE therapy compared with placebo added on to standard SLE therapy. We're running this trial in patients whose disease remains persistently active or who flare frequently, even while on stable standard of care. Much like the Phase I and Phase II, we'll be assessing efficacy through BILAG-based Composite Lupus Assessment, or BICLA. However, unlike the Phase II study, this one spans 48 weeks to show the effect over the long term. We also enlarged the sample size so we'd have a substantial data set covering safety and efficacy. Ultimately and in the end, we'll be seeking a meaningful change on the primary endpoint and key secondaries, including prevention of severe flares and patients reaching low-dose activity. And we genuinely believe BICLA is a sensitive, clinically meaningful composite for SLE disease activity that demands disease improvement across all body symptoms with moderate or severe baseline activity, without requiring escalation in steroids or other background medications, and without worsening. So alongside an acceptable safety and tolerability profile, we're eagerly awaiting this. We believe it could be truly meaningful for patients who suffer from SLE. So should the results justify continued development, at this point we anticipate needing to conduct another Phase III, though we're currently planning some of that at risk.

Eric Schmidt

analyst
#27

Chris, maybe today's call looks like something of a relative peak during your time leading the company, considering several programs that are now solidly established and everything you've achieved. And you definitely highlighted that in your prepared remarks. You also pointed out that there are challenges ahead and the work isn't finished; so what specifically is foremost on your mind there?

Chris Viehbacher

executive
#28

Well, I appreciate the question. My hope is that this isn't the peak, since our ambitions run considerably higher, I can assure you. Clearly, we still have an MS franchise where — we haven't finished dealing with the competitive threats. A biosimilar for TYSABRI could emerge. There's a significant patent litigation coming this fall concerning TECFIDERA in Europe, plus market exclusivity that runs out in February. So over the near term, there's always turbulence. But I believe our opportunity lies in having a remarkable talent pool within Biogen. As all of you are aware, I've spent many years in this industry, observed plenty of companies. I remain consistently struck by the scientific and medical expertise present in our organization, and we possess capital. Thus I believe we're able to make wise moves with that capital. We've been occupied converting what was essentially passive capital into active capital; we had 2 priority review vouchers sitting unused. Biogen's products are innovative enough that those vouchers aren't really necessary, given the novel products we launch regardless. So we had this single priority review voucher sitting unused for 6 years, which we've now turned, hopefully, into an active asset. We sold it, though the aim is to direct that money toward milestones and business development during the second half. Looking at HI-Bio, we took 1.5 years of Fit for Growth savings from operating expense and converted that into a growth opportunity through acquiring HI-Bio. So my view of where we stand is that we've managed to alter the company's trajectory. We've managed to free up resources from the business and redeploy them wisely. And we have excellent people who I believe can deliver tremendous results doing so; therefore, looking ahead, it's really about expanding the R&D portfolio now, both internally and externally. I want to ensure we remain an innovation company going forward, that we aren't merely buying our future but genuinely investing in it. So my focus now is on the 2025 to 2030 time frame. I believe we're well positioned to grow throughout that period. Yet I think we can do more to truly leverage our R&D capability. So I believe what you're going to observe is that we keep putting money to work, doing so very carefully, yet I expect we can transform capital that's sitting passively into capital that's active, and from there into growth that's active.

Chuck Triano

executive
#29

Okay, thanks, Chris, and thanks to all of you for being here with us today. Anyone with further questions can reach out to the IR team, who will stay available. Thanks.

Operator

operator
#30

That brings us to the end of today's call. We appreciate everyone for joining in. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.